- Home
- TNET vs DNLI Comparison
TNET vs DNLI Comparison
Compare TNET & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNET | DNLI |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TNET | DNLI |
|---|---|---|
| Price | $68.75 | $24.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $65.80 | $34.33 |
| AVG Volume (30 Days) | 421.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $408.85 |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $12.58 |
| 52 Week High | $73.08 | $27.30 |
Technical Indicators
Market Signals| Indicator | TNET | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 52.33 |
| Support Level | $55.63 | $22.32 |
| Resistance Level | $73.08 | $25.74 |
| Average True Range (ATR) | 3.60 | 0.90 |
| MACD | -0.49 | 0.06 |
| Stochastic Oscillator | 51.58 | 59.84 |
Price Performance
Historical ComparisonAbout TNET TriNet Group Inc.
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.